Goldman Sachs initiated coverage of Immunome (IMNM) with a Buy rating and $26 price target The firm says Immunome is developing best- or first-in-class targeted oncology therapeutics. Goldman is positive into the Phase 3 RINGSIDE results in patients with desmoid tumors, with data expected at the end of 2025. Varegacestat is “differentiated” over Merck KGaA’s Ogsiveo, with best-in-class potential, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome announces novel antibody collaboration with Infinimmune
- Immunome initiated with a Buy at Craig-Hallum ahead of near-term catalysts
- Immunome initiated with a Buy at Craig-Hallum
- Immunome’s Varegacestat: Promising Phase 3 Prospects and Competitive Edge in Desmoid Tumor Treatment
- Gap downgraded, Ulta upgraded: Wall Street’s top analyst calls